AUTHORS ' CONCLUSIONS Addition of ox and rolone to the GH therapy led to a modest increase in the final adult height of girls aged up to 18 years with TS .
BACKGROUND The final adult height of untreated girls aged up to 18 years with Turner syndrome ( TS ) is approximately 20 cm shorter compared with healthy females .
Treatment with growth hormone ( GH ) increases the adult height of people with TS .
The effects of adding the and rogen , ox and rolone , in addition to GH are unclear .
Therefore , we conducted this systematic review to investigate the benefits and harms of ox and rolone as an adjuvant therapy for people with TS treated with GH .
OBJECTIVES To assess the effects of ox and rolone on growth hormone-treated girls aged up to 18 years with Turner syndrome .
Results from the First 2 Years of a Clinical Trial with Recombinant DNA‐derived Human Growth Hormone (Somatrem) in Turner's Syndrome
A total of 70 subjects with Turner 's syndrome from 11 centres were enrolled in a study of somatrem . After an initial observation period , they were r and omly assigned to one of four groups , receiving no treatment ( Group 1 , control ) ; ox and rolone , 0.125 mg/kg/day ( Group 2 ) ; somatrem , 0.125 mg/kg 3 times/week ( Group 3 ) ; or a combination of somatrem and ox and rolone on the above dose regimens ( Group 4 ) . After 12–20 months , Groups 1 ( control ) , 2 ( ox and rolone ) and 4 ( combination ) were treated with somatrem , 0.125 mg/kg 3 times/week , and ox and rolone , 0.0625 mg/kg/day ; Group 3 remained on somatrem , 0.125 mg/kg 3 times/week . All three treatment groups showed a statistically significant increase during year 1 in growth velocity over both their pretreatment growth rates and the control group growth rate . These increases were slightly less in year 2 for the somatrem and combination therapy groups , but remained significantly higher than the year 1 control group growth rate . Plasma IGF‐1 levels were elevated in years 1 and 2 in the somatrem and combination groups . Adverse events were few with the somatrem group , though mild virilization occurred with ox and rolone , alone or in combination . Bone age advancement was observed with all treatments but was greater with combination therapy ; it was accompanied by height age advancement . The effect of this therapy on predicted adult height was also evaluated
AUTHORS ' CONCLUSIONS Addition of ox and rolone to the GH therapy led to a modest increase in the final adult height of girls aged up to 18 years with TS .
BACKGROUND The final adult height of untreated girls aged up to 18 years with Turner syndrome ( TS ) is approximately 20 cm shorter compared with healthy females .
Treatment with growth hormone ( GH ) increases the adult height of people with TS .
The effects of adding the and rogen , ox and rolone , in addition to GH are unclear .
Therefore , we conducted this systematic review to investigate the benefits and harms of ox and rolone as an adjuvant therapy for people with TS treated with GH .
OBJECTIVES To assess the effects of ox and rolone on growth hormone-treated girls aged up to 18 years with Turner syndrome .